2007 2010 Safety Treatment 
Cannabis Law Report
MAY 26, 2022
So we need to discuss openly and critically how we can remain balanced and ensure the potential of psychedelics can be optimised without compromising safety.”. Since 2007 our focus has been on high-quality science”, said Breeksema. And how do we make sure treatments are safe, accessible, and inclusive?
Cannabis Law Report
JANUARY 23, 2022
At current, transplant treatments are hindered by our understanding of the immune response of those receiving treatments. More than 25,000 hematopoietic stem cell transplantations (HSCTs) are performed each year for the treatment of lymphoma, leukemia, immune-de?ciency doi: 10.1182/BLOOD-2010-12-323824. Burstein, S.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Greencamp
APRIL 23, 2019
For patients who don’t respond well to conventional MS methods, cannabis treatment seems like a very reasonable choice. Since so little is known about the exact cause of this condition, and a cure hasn’t been found yet, treatment options are limited but they do exist. What is multiple sclerosis? Scientific research on cannabis and MS.
Cannabis Law Report
JULY 16, 2019
The 40-year-old northeast Pennsylvanian native was diagnosed with Hodgkin’s lymphoma in 2010. Within months he realized he was going to have to grow his own cannabis to cut down on the cost of treatment. He still recoils when recalling his experience with mainstream medical treatment. Mike Rubin lives on borrowed time.
Cannabis Law Report
NOVEMBER 24, 2021
However, the nature of the government regulations and the subsequent complexity of prescribing, as well as doctors’ safety uncertainties and the stigma of the plant, remain contributing barriers to patient access. It was also used as a topical treatment for haemorrhoids, ear infection, and wounds (Aldrich 1997 ; Touw 1981 ).
Cannabis Law Report
APRIL 8, 2022
This year, we are completing the second Phase 3 clinical trial of MDMA-assisted therapy for PTSD , the final stage prior to requesting FDA approval for a new prescription treatment to help heal trauma. MAPS completed the first Phase 1 safety study with MDMA and resumed working on a protocol for anxiety associated with cancer.
Cannabis Law Report
OCTOBER 29, 2019
ElleVet Sciences is pleased to announce the results and publication of the first safety study on the use of hemp CBD/CBDA. The 12-week safety study, conducted by Dr. Joseph Wakshlag, DVM, Ph.D., Dr. Wakshlag is currently available for interviews to discuss the results of the safety study as well as his clinical trials.
Expert insights. Personalized for you.
52 
Let's personalize your content